Key result
P2Y12 inhibitor prescriptions lacked documented therapeutic duration in 27.0% of veterans and were continued beyond the intended stop date in 8.4% of patients.
Observational (n=1,100)
No
Answers are grounded in this paper and cite their sources.
More than one-fourth of veterans prescribed a P2Y12 inhibitor lacked clear EHR documentation of intended treatment duration and 8.4% continued therapy past their planned stop date, highlighting a critical quality gap addressable through structured EHR tools and automated alerts.
Background: The use of P2Y 12 inhibitor is highly variable, and administration is frequently confounded by inconsistent documentation that heightens risks for mismanagement, particularly following transitions of care. Project Rationale: Insufficient documentation clearly defining the indication and therapeutic duration for antiplatelet agents carries potential risks for bleeding and/or ischemia. This was observed in patients who were veterans and was felt to represent a modifiable quality gap. Project Summary: A 2-phase quality improvement initiative at the New Mexico Veterans Affairs Health Care System reviewed documentation among 1,100 veterans prescribed a P2Y 12 inhibitor. In a randomly selected sample of 135 patients, 27% lacked documentation clearly defining therapeutic duration, and 8.4% continued P2Y 12 inhibitor beyond the intended stop date. A structured electronic health record document and automated reminders were developed using a Plan-Do-Study-Act framework to address these concerns. Take-Home Message: Structured electronic health record documentation with automated reminders can improve antiplatelet stewardship and safety.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) conducted an observational in Cardiovascular or cerebrovascular conditions requiring P2Y12 inhibitor therapy (n=1,100). P2Y12 inhibitor prescription was evaluated on Lack of clear documentation regarding intended duration of P2Y12 inhibitor therapy. P2Y12 inhibitor prescriptions lacked documented therapeutic duration in 27.0% of veterans and were continued beyond the intended stop date in 8.4% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: